{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:31:57Z","timestamp":1788294717200,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006525","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T16:58:06Z","timestamp":1490720286000},"page":"e6525","source":"Crossref","is-referenced-by-count":3,"title":["The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis"],"prefix":"10.1097","volume":"96","author":[{"given":"Kuang-Ming","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Teng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-58-20210309","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(05)17789-7","article-title":"Chronic kidney disease: the global challenge","volume":"365","author":"El Nahas","year":"2005","journal-title":"Lancet"},{"key":"R2-58-20210309","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.ki.5002343","article-title":"Chronic kidney disease as a global public health problem: approaches and initiatives\u2014a position statement from Kidney Disease Improving Global Outcomes","volume":"72","author":"Levey","year":"2007","journal-title":"Kidney Int"},{"key":"R3-58-20210309","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1797.2010.01304.x","article-title":"Epidemiology, impact and preventive care of chronic kidney disease in Taiwan","volume":"15","author":"Hwang","year":"2010","journal-title":"Nephrology (Carlton"},{"key":"R4-58-20210309","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfn406","article-title":"Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance","volume":"23","author":"Yang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R5-58-20210309","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1523-1755.2005.09800.x","article-title":"Prevention of chronic kidney and vascular disease: toward global health equity-the Bellagio 2004 Declaration","volume":"98","author":"Dirks","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"R6-58-20210309","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/ajkd.2001.27392","article-title":"Cardiovascular disease in end-stage renal disease patients","volume":"38","author":"Collins","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R7-58-20210309","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"R8-58-20210309","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R9-58-20210309","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R10-58-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R11-58-20210309","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-58-20210309","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-58-20210309","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R14-58-20210309","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-58-20210309","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","article-title":"Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients","volume":"80","author":"Chan","year":"2011","journal-title":"Kidney Int"},{"key":"R16-58-20210309","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/aps.2010.159","article-title":"Genetic analysis of six SNPs in candidate genes associated with high cross-race risk of development of thoracic aortic aneurysms and dissections in Chinese Han population","volume":"31","author":"Liu","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"R17-58-20210309","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/aps.2013.179","article-title":"Association of the polymorphisms of MMP-9 and TIMP-3 genes with thoracic aortic dissection in Chinese Han population","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"R18-58-20210309","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","article-title":"Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan","volume":"20","author":"Cheng","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R19-58-20210309","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","article-title":"Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice","volume":"21","author":"Farmer","year":"1999","journal-title":"Clin Ther"},{"key":"R20-58-20210309","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1176\/ps.2007.58.6.864","article-title":"Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness","volume":"58","author":"Woltmann","year":"2007","journal-title":"Psychiatr Serv"},{"key":"R21-58-20210309","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ki.2013.103","article-title":"Adherence to antihypertensive agents improves risk reduction of end-stage renal disease","volume":"84","author":"Roy","year":"2013","journal-title":"Kidney Int"},{"key":"R22-58-20210309","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-12-44","article-title":"Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study","volume":"12","author":"Bansal","year":"2011","journal-title":"BMC Nephrol"},{"key":"R23-58-20210309","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"R24-58-20210309","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"R25-58-20210309","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R26-58-20210309","doi-asserted-by":"crossref","first-page":"478597","DOI":"10.1155\/2013\/478597","article-title":"Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials","volume":"2013","author":"Ong","year":"2013","journal-title":"ISRN Cardiol"},{"key":"R27-58-20210309","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R28-58-20210309","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2012.139","article-title":"Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study","volume":"172","author":"Bajaj","year":"2012","journal-title":"Arch Intern Med"},{"key":"R29-58-20210309","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:46:55Z","timestamp":1620960415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703310-00058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006525","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}